Results 161 to 170 of about 2,675,009 (295)

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source

Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: a report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative

, 2004
Bertram L. Kasiske, Borja G. Cosío, Judith A. Beto, K Bolton, Blanche M. Chavers, Richard H. Grimm, Adeera Levin, Bassam A. Masri, Rulan S. Parekh, Christoph Wanner, David C. Wheeler, Peter W.F. Wilson   +11 more
openalex   +1 more source

Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled Phase III Clinical Experience Acquired with Raptiva (CLEAR) trial [NCT00256139] [PDF]

, 2005
Jean‐Paul Ortonne, Neil H. Shear, Stephen Shumack, Eric Henninger   +3 more
openalex   +1 more source

Association of high‐dose radioactive iodine therapy with PPM1D‐mutated clonal hematopoiesis in older individuals

Molecular Oncology, EarlyView.
In thyroid cancer patients, high‐dose (≥7.4 GBq) radioactive iodine therapy (RAIT) was associated with a higher prevalence of clonal hematopoiesis (variant allele frequency >2%) in individuals aged ≥50 years (OR = 2.44). In silico analyses showed that truncating PPM1D mutations conferred a selective advantage under these conditions.
Jaeryuk Kim, Sungwoo Bae, Jaeyong Choi, Sun‐Wha Im, Bukyoung Cha, Gyeongseo Jung, Sun Wook Cho, Eul‐Ju Seo, Young Ah Lee, Jin Chul Paeng, Young Joo Park, Jong‐Il Kim   +11 more
wiley   +1 more source

Patient Reported Outcome Measurements in Adult Spinal Deformity: A Narrative Review. [PDF]

Global Spine J
Kelly MP, Smith JS, van Hooff M.
europepmc   +1 more source

Metaanalysis of the correlation between radiographic tumor response and patient‐reported outcomes [PDF]

, 2005
David Victorson, M. Soni, David Cella
openalex   +1 more source

Patient-reported outcomes in the spotlight [PDF]

The Lancet Neurology, 2019
openaire   +2 more sources

Patient-reported outcome measures and orthodontics [PDF]

Journal of Orthodontics, 2018
Ryan, FS, Cunningham, SJ
openaire   +4 more sources

ITGAV and SMAD4 influence the progression and clinical outcome of pancreatic ductal adenocarcinoma

Molecular Oncology, EarlyView.
In SMAD4‐positive pancreatic ductal adenocarcinoma (PDAC), integrin subunit alpha V (ITGAV) activates latent TGF‐β, which binds to the TGF‐β receptor and phosphorylates SMAD2/3. The activated SMAD2/3 forms a complex with SMAD4, and together they translocate to the nucleus, modulating gene expression to promote proliferation, migration, and invasion. In
Daniel K. C. Lee, Keyue Chen, Ryan Loke, Xiang Li, David Liubart, Golam T. Saffi, Jonathan T. S. Chow, Ché M. P. Melo, Lydia To, Leonardo Salmena   +9 more
wiley   +1 more source

Variations in quantifying patient reported outcome measures to estimate treatment effect. [PDF]

World J Methodol
Muthu S, Vadranapu S.
europepmc   +1 more source